INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, is pleased to report that its Phase I/II trial (the “CaRe PC” trial) of INKmune™ for men with ...

Shares of INmune Bio climbed after the biotech company said its trial for treatment of a certain prostate cancer met its targets. The stock was up 11%, to $2.83, but is still down 65% over the ...

Investing.com -- INmune Bio Inc. (NASDAQ: INMB) stock surged 28% after the company announced its Phase I/II trial of INKmune™ in metastatic castration-resistant prostate cancer (mCRPC) met both ...

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage ...

INmune Bio Inc. (NASDAQ:INMB) saw its stock jump 28% on Monday after announcing that its Phase I/II trial evaluating INKmune™ ...

Pre-earnings options volume in INmune Bio (INMB) is normal with calls leading puts 10:7. Implied volatility suggests the market is anticipating a ...

Shares of Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) were trading at $393.83, down $78.44, or 16%, on top-line results from the phase II dose-ranging study evaluating the safety and efficacy of its ...

Stingray Group (TSX: RAY. A; RAY.B), an industry leader in music and video content distribution, business services, and ...

BIO 2025 brings pharma, biotech, and policy leaders together to tackle industry challenges. Follow our coverage on AI, vaccines, cell & gene therapy, and key discussions from health officials.